Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The reco...
Gespeichert in:
| Veröffentlicht in: | Annals of neurology 1997-09, Vol.42 (3), p.379-382 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 382 |
|---|---|
| container_issue | 3 |
| container_start_page | 379 |
| container_title | Annals of neurology |
| container_volume | 42 |
| creator | Rudick, Richard Antel, Jack Confavreux, Christian Cutter, Gary Ellison, George Fischer, Jill Lublin, Fred Miller, Aaron Petkau, John Rao, Stephen Reingold, Stephen Syndulko, Karl Thompson, Alan Wallenberg, Joy Weinshenker, Brian Willoughby, Ernest |
| description | This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated. |
| doi_str_mv | 10.1002/ana.410420318 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79303574</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79303574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4698-6728832bca542a56c04ec377ae049f1ab010caaf17ee215f274dd9d444a55f2b3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EKkvhyBHJB9Rbij_j5LiqaEFaispXj9asMxGmTrJkEpX99zXdaMWJk2XP43dmHsZeS3EuhVDvoIdzI4VRQsvqCVtJq2VRKVM_ZSuhS1NYqc1z9oLolxCiLqU4YSe1Fk6VesWaLxiGrsO-gSkOPfF2HDo-_UTePz5A4t2cprhLyCkkHAeKxGkIEac9Dyn2MWRmmKccg8SBCIly3sQnoDveDmPAl-xZC4nw1XKesu-X779dfCg2n68-Xqw3RTBlXRWlU1Wl1TaANQpsGYTBoJ0DFKZuJWyFFAGglQ5RSdsqZ5qmbowxYPNtq0_Z2SF3Nw6_Z6TJd5ECpgQ9DjN5l9fW1pkMFgcw5H1oxNbvxtjBuPdS-L9Wfbbqj1Yz_2YJnrcdNkd60Zjrb5c6UNbRjtCHSEdMVVqrx7bugN3HhPv_9_Tr6_W_AywDR5rwz_EnjHe-dNpZf3t95X_YT7eX-uar3-gHq8ygrg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79303574</pqid></control><display><type>article</type><title>Recommendations from the national multiple sclerosis society clinical outcomes assessment task force</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rudick, Richard ; Antel, Jack ; Confavreux, Christian ; Cutter, Gary ; Ellison, George ; Fischer, Jill ; Lublin, Fred ; Miller, Aaron ; Petkau, John ; Rao, Stephen ; Reingold, Stephen ; Syndulko, Karl ; Thompson, Alan ; Wallenberg, Joy ; Weinshenker, Brian ; Willoughby, Ernest</creator><creatorcontrib>Rudick, Richard ; Antel, Jack ; Confavreux, Christian ; Cutter, Gary ; Ellison, George ; Fischer, Jill ; Lublin, Fred ; Miller, Aaron ; Petkau, John ; Rao, Stephen ; Reingold, Stephen ; Syndulko, Karl ; Thompson, Alan ; Wallenberg, Joy ; Weinshenker, Brian ; Willoughby, Ernest</creatorcontrib><description>This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated.</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.410420318</identifier><identifier>PMID: 9307263</identifier><identifier>CODEN: ANNED3</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Biological and medical sciences ; Clinical Trials as Topic - standards ; Humans ; Medical sciences ; Multiple Sclerosis - diagnosis ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology</subject><ispartof>Annals of neurology, 1997-09, Vol.42 (3), p.379-382</ispartof><rights>Copyright © 1997 the American Neurological Association</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4698-6728832bca542a56c04ec377ae049f1ab010caaf17ee215f274dd9d444a55f2b3</citedby><cites>FETCH-LOGICAL-c4698-6728832bca542a56c04ec377ae049f1ab010caaf17ee215f274dd9d444a55f2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.410420318$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.410420318$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,1411,23911,23912,25120,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2833274$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9307263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rudick, Richard</creatorcontrib><creatorcontrib>Antel, Jack</creatorcontrib><creatorcontrib>Confavreux, Christian</creatorcontrib><creatorcontrib>Cutter, Gary</creatorcontrib><creatorcontrib>Ellison, George</creatorcontrib><creatorcontrib>Fischer, Jill</creatorcontrib><creatorcontrib>Lublin, Fred</creatorcontrib><creatorcontrib>Miller, Aaron</creatorcontrib><creatorcontrib>Petkau, John</creatorcontrib><creatorcontrib>Rao, Stephen</creatorcontrib><creatorcontrib>Reingold, Stephen</creatorcontrib><creatorcontrib>Syndulko, Karl</creatorcontrib><creatorcontrib>Thompson, Alan</creatorcontrib><creatorcontrib>Wallenberg, Joy</creatorcontrib><creatorcontrib>Weinshenker, Brian</creatorcontrib><creatorcontrib>Willoughby, Ernest</creatorcontrib><title>Recommendations from the national multiple sclerosis society clinical outcomes assessment task force</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated.</description><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic - standards</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EKkvhyBHJB9Rbij_j5LiqaEFaispXj9asMxGmTrJkEpX99zXdaMWJk2XP43dmHsZeS3EuhVDvoIdzI4VRQsvqCVtJq2VRKVM_ZSuhS1NYqc1z9oLolxCiLqU4YSe1Fk6VesWaLxiGrsO-gSkOPfF2HDo-_UTePz5A4t2cprhLyCkkHAeKxGkIEac9Dyn2MWRmmKccg8SBCIly3sQnoDveDmPAl-xZC4nw1XKesu-X779dfCg2n68-Xqw3RTBlXRWlU1Wl1TaANQpsGYTBoJ0DFKZuJWyFFAGglQ5RSdsqZ5qmbowxYPNtq0_Z2SF3Nw6_Z6TJd5ECpgQ9DjN5l9fW1pkMFgcw5H1oxNbvxtjBuPdS-L9Wfbbqj1Yz_2YJnrcdNkd60Zjrb5c6UNbRjtCHSEdMVVqrx7bugN3HhPv_9_Tr6_W_AywDR5rwz_EnjHe-dNpZf3t95X_YT7eX-uar3-gHq8ygrg</recordid><startdate>199709</startdate><enddate>199709</enddate><creator>Rudick, Richard</creator><creator>Antel, Jack</creator><creator>Confavreux, Christian</creator><creator>Cutter, Gary</creator><creator>Ellison, George</creator><creator>Fischer, Jill</creator><creator>Lublin, Fred</creator><creator>Miller, Aaron</creator><creator>Petkau, John</creator><creator>Rao, Stephen</creator><creator>Reingold, Stephen</creator><creator>Syndulko, Karl</creator><creator>Thompson, Alan</creator><creator>Wallenberg, Joy</creator><creator>Weinshenker, Brian</creator><creator>Willoughby, Ernest</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Willey-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199709</creationdate><title>Recommendations from the national multiple sclerosis society clinical outcomes assessment task force</title><author>Rudick, Richard ; Antel, Jack ; Confavreux, Christian ; Cutter, Gary ; Ellison, George ; Fischer, Jill ; Lublin, Fred ; Miller, Aaron ; Petkau, John ; Rao, Stephen ; Reingold, Stephen ; Syndulko, Karl ; Thompson, Alan ; Wallenberg, Joy ; Weinshenker, Brian ; Willoughby, Ernest</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4698-6728832bca542a56c04ec377ae049f1ab010caaf17ee215f274dd9d444a55f2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic - standards</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rudick, Richard</creatorcontrib><creatorcontrib>Antel, Jack</creatorcontrib><creatorcontrib>Confavreux, Christian</creatorcontrib><creatorcontrib>Cutter, Gary</creatorcontrib><creatorcontrib>Ellison, George</creatorcontrib><creatorcontrib>Fischer, Jill</creatorcontrib><creatorcontrib>Lublin, Fred</creatorcontrib><creatorcontrib>Miller, Aaron</creatorcontrib><creatorcontrib>Petkau, John</creatorcontrib><creatorcontrib>Rao, Stephen</creatorcontrib><creatorcontrib>Reingold, Stephen</creatorcontrib><creatorcontrib>Syndulko, Karl</creatorcontrib><creatorcontrib>Thompson, Alan</creatorcontrib><creatorcontrib>Wallenberg, Joy</creatorcontrib><creatorcontrib>Weinshenker, Brian</creatorcontrib><creatorcontrib>Willoughby, Ernest</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rudick, Richard</au><au>Antel, Jack</au><au>Confavreux, Christian</au><au>Cutter, Gary</au><au>Ellison, George</au><au>Fischer, Jill</au><au>Lublin, Fred</au><au>Miller, Aaron</au><au>Petkau, John</au><au>Rao, Stephen</au><au>Reingold, Stephen</au><au>Syndulko, Karl</au><au>Thompson, Alan</au><au>Wallenberg, Joy</au><au>Weinshenker, Brian</au><au>Willoughby, Ernest</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommendations from the national multiple sclerosis society clinical outcomes assessment task force</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>1997-09</date><risdate>1997</risdate><volume>42</volume><issue>3</issue><spage>379</spage><epage>382</epage><pages>379-382</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><coden>ANNED3</coden><abstract>This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>9307263</pmid><doi>10.1002/ana.410420318</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-5134 |
| ispartof | Annals of neurology, 1997-09, Vol.42 (3), p.379-382 |
| issn | 0364-5134 1531-8249 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79303574 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Clinical Trials as Topic - standards Humans Medical sciences Multiple Sclerosis - diagnosis Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology |
| title | Recommendations from the national multiple sclerosis society clinical outcomes assessment task force |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A39%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommendations%20from%20the%20national%20multiple%20sclerosis%20society%20clinical%20outcomes%20assessment%20task%20force&rft.jtitle=Annals%20of%20neurology&rft.au=Rudick,%20Richard&rft.date=1997-09&rft.volume=42&rft.issue=3&rft.spage=379&rft.epage=382&rft.pages=379-382&rft.issn=0364-5134&rft.eissn=1531-8249&rft.coden=ANNED3&rft_id=info:doi/10.1002/ana.410420318&rft_dat=%3Cproquest_cross%3E79303574%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79303574&rft_id=info:pmid/9307263&rfr_iscdi=true |